Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER(R), RE-COVER™ II, and RE-MEDY™

In conclusion, the efficacy and safety of dabigatran etexilate were not significantly affected by the presence of thrombophilia or APS. ClinicalTrials.gov RECOVER Identifier: NCT00291330; RECOVER II Identifier: NCT00680186; RE-MEDY Identifier: NCT00329238

Source: Vascular Medicine - November 28, 2016 Category: Internal Medicine Authors: Goldhaber, S. Z., Eriksson, H., Kakkar, A., Schellong, S., Feuring, M., Fraessdorf, M., Kreuzer, J., Schueler, E., Schulman, S. Tags: Original Articles Source Type: research